The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials

Mads Ammitzbøll-Danielsen; Mikkel Østergaard; Esperanza Naredo; Annamaria Iagnocco; Ingrid Möller; Maria-Antonietta D'Agostino; Frédérique Gandjbakhch; Lene Terslev

doi:10.3899/jrheum.170501

The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials

Mads Ammitzbøll-Danielsen, Mikkel Østergaard, Esperanza Naredo, Annamaria Iagnocco, Ingrid Möller, Maria-Antonietta D'Agostino, Frédérique Gandjbakhch, Lene Terslev

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

8 Citationer (Scopus)

Abstract

OBJECTIVE: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design.

METHODS: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system.

RESULTS: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean ≥ 0.8).

CONCLUSION: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

Originalsprog	Engelsk
Tidsskrift	Journal of Rheumatology
Vol/bind	45
Udgave nummer	2
Sider (fra-til)	165-169
Antal sider	5
ISSN	0315-162X
DOI	https://doi.org/10.3899/jrheum.170501
Status	Udgivet - feb. 2018

Adgang til dokumentet

10.3899/jrheum.170501

Citationsformater

@article{6110b36535a34429bc87db04aa62b0b7,

title = "The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials",

abstract = "OBJECTIVE: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design.METHODS: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system.RESULTS: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean ≥ 0.8).CONCLUSION: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.",

author = "Mads Ammitzb{\o}ll-Danielsen and Mikkel {\O}stergaard and Esperanza Naredo and Annamaria Iagnocco and Ingrid M{\"o}ller and Maria-Antonietta D'Agostino and Fr{\'e}d{\'e}rique Gandjbakhch and Lene Terslev",

note = "COPECARE",

year = "2018",

month = feb,

doi = "10.3899/jrheum.170501",

language = "English",

volume = "45",

pages = "165--169",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "2",

}

TY - JOUR

T1 - The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials

AU - Ammitzbøll-Danielsen, Mads

AU - Østergaard, Mikkel

AU - Naredo, Esperanza

AU - Iagnocco, Annamaria

AU - Möller, Ingrid

AU - D'Agostino, Maria-Antonietta

AU - Gandjbakhch, Frédérique

AU - Terslev, Lene

N1 - COPECARE

PY - 2018/2

Y1 - 2018/2

N2 - OBJECTIVE: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design.METHODS: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system.RESULTS: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean ≥ 0.8).CONCLUSION: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

AB - OBJECTIVE: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design.METHODS: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system.RESULTS: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean ≥ 0.8).CONCLUSION: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

U2 - 10.3899/jrheum.170501

DO - 10.3899/jrheum.170501

M3 - Journal article

C2 - 29247153

SN - 0315-162X

VL - 45

SP - 165

EP - 169

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 2

ER -

The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater